Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01252186 · ClinicalTrials.gov registry record · Phase 2
A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women
A Phase 2 study, sponsored by Teva Women's Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 265
- Enrollment target
NCT01252186 is a Phase 2 study that has completed, run by Teva Women's Health. The registered enrollment target is 265 participants.
The verdict
NCT01252186, a Phase 2 study, has completed, sponsored by Teva Women's Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 265 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the impact of a 91-day extended cycle oral contraceptive compared to two 28-day oral contraceptive regimens on hemostatic parameters in healthy women.
Interventions
- DRUG 91-day Levonorgestrel Oral Contraceptive
- DRUG 28-day Levonorgestrel Oral Contraceptive
- DRUG 28-day Desogestrel Oral Contraceptive
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01252186
The ClinicalTrials.gov registry entry for NCT01252186 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Women's Health, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 91-day Levonorgestrel Oral Contraceptive is the first listed.
NCT01252186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01252186 about?
NCT01252186 is a clinical study titled "A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women". This study is being conducted to evaluate the impact of a 91-day extended cycle oral contraceptive compared to two 28-day oral contraceptive regimens on hemostatic parameters in healthy women.
What is the current status of trial NCT01252186?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 265 participants. The study started on 2010-11. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01252186?
The interventions under investigation include: 91-day Levonorgestrel Oral Contraceptive (DRUG), 28-day Levonorgestrel Oral Contraceptive (DRUG), 28-day Desogestrel Oral Contraceptive (DRUG).
Who is sponsoring clinical trial NCT01252186?
This trial is sponsored by Teva Women's Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.